期刊文献+

氯吡格雷通过上调miR-145表达抑制VSMC增殖的机制研究 被引量:1

Study on the Mechanism of Inhibiting VSMC Proliferation by up Regulating miR-145 Expressionby Clopidogrel
下载PDF
导出
摘要 目的本研究旨在探究miR-145是否对血管平滑肌细胞(VSMC)的增殖起调控作用,以及氯吡格雷如何通过调控CD40来发挥其消炎作用,以期为氯吡格雷的药用作用发挥提供新的理论依据。方法实验分组为(1)DMSO组,即溶剂对照组;(2)TNF-α组;(3)miR-145抑制剂对照组;(4)氯吡格雷组;(5)miR-145抑制剂+氯吡格雷组。并通过Ed U标记检测细胞增殖;qRT-PCR用于检测miR-145,CD40和VSMC中Calponin mRNA的表达;Western blot检测CD40的蛋白表达水平;通过ELISA检测细胞培养物上清液中IL-6的水平。结果与氯吡格雷组相比,miR-145抑制剂+氯吡格雷组的Calponin mRNA水平降低(P<0.01);与DMSO组相比,TNF-α组的miR-145 mRNA水平下降(P<0.01);与TNF-α组相比,氯吡格雷组的miR-145 mRNA水平上升(P<0.01);与氯吡格雷组相比,miR-145抑制剂+氯吡格雷组的miR-145 mRNA水平下降(P<0.01)。miR-145抑制剂对照组不影响CD40的水平;与DMSO组相比,TNF-α组的CD40 mRNA水平上升(P<0.01);与TNF-α组相比,氯吡格雷组的CD40 mRNA水平下降(P<0.01);与氯吡格雷组相比,miR-145抑制剂+氯吡格雷组的CD40 mRNA水平上升(P<0.01)。TNF-α组上清液中IL-6的水平高于DMSO组(P<0.01);氯吡格雷组中IL-6水平低于TNF-α组(P<0.01);miR-145抑制剂+氯吡格雷组IL-6的水平高于氯吡格雷组(P<0.01)。结论氯吡格雷通过抑制CD40的表达,诱导miR-145抑制VSMC细胞增殖并发挥消炎作用。 Objective To investigate whether miR-145 is involved in the regulation of vascular smooth muscle cell (VSMC) proliferation and to determine the anti-inflammatory effects of clopidogrel via its regulation of CD40 for providing a new theoretical basis for the pharmacological effect of clopidogrel.Methods The TNF-α induced proliferation models of VSMC were divided into different groups with or without clopidogrel.RT-PCR was used to detect mRNA expression of miR-145, CD40 and Calponin (a VSMC differentiation marker gene).Western blot was used to detect CD40 protein expression;ELISA was used to determine the concentration of inflammatory cytokine IL-6 in the supernatant of cells.Results Compared with the clopidogrel group, the Calponin and mRNA levels in the miR-145 inhibitor + clopidogrel group decreased significantly (P〈0.01).Compared with DMSO group, TNF-group of miR-145 alpha mRNA decreased significantly (P〈0.01);compared with the TNF-Alpha group, clopidogrel group had significantly increased miR-145 levels (P〈0.01);compared with clopidogrel group, clopidogrel/miR-145 group had reduced the mRNA level of miR-145 (P〈0.01).In control group, miR-145 inhibitors did not affect CD40 level;compared with DMSO group, in TNF-group, CD40 mRNA alpha level increased (P〈0.01);compared with the TNF-Alpha Group, in clopidogrel group CD40 mRNA decreased (P〈0.01);compared with clopidogrel group, in miR-145 inhibitor + clopidogrel group, the mRNA level of CD40 increased (P〈0.01).The concentration of IL-6 in supernatant of TNF-group was higher than that in DMSO group (P〈0.01).The IL-6 concentration in the clopidogrel group was lower than that in the TNF group (P〈0.01).The concentration of IL-6 in the +miR-145 inhibitor + clopidogrel group was higher than that in the clopidogrel group (P〈0.01).Conclusion miR-145 is involved in the anti-proliferative and anti-inflammatory effects of clopidogrel on VSMCs by inhibiting the expression of CD40.
出处 《标记免疫分析与临床》 CAS 2017年第7期796-802,共7页 Labeled Immunoassays and Clinical Medicine
基金 2012年国家青年科学基金项目(81100166)
关键词 氯吡格雷 MIR-145 CD40 血管平滑肌细胞 增殖 Clopidogrel VSMC Proliferation
  • 相关文献

参考文献1

二级参考文献19

  • 1Puskarich M A, Shapiro N I, Trzeciak S, et al. Plasma levels of mitochondrial DNA in patients presenting to the emergency department with sepsis. Shock, 2012, 38 (4) :337-340.
  • 2Zhao Y, Li C, Jia Y. Evaluation of Mortality in Emergency Department Sepsis score combined with procalcitionin in septic patients. Am J Emerg Med, 2013, 31(7) :1086-1091.
  • 3. Levy M M,Fink M P, Marshall J C, et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definition Conference. Crit Care Med, 2003, 31 (4) :1250-1256.
  • 4KozielJ, Bryzek D, Sroka A, et al. Citrullination alters immunomodulatory function of LL-37 essential for prevention of endotoxin-indueed sepsis. J Immunol, 2014, 192 ( 11 ):5363-5372.
  • 5Claeys R,Vinken S, Spapen H, et al. Plasma procalcitonin and C-reactive protein in acute septic shock: clinical and biological corredates. Crit Care Med, 2002, 30(4) :757-762.
  • 6Balcl C, Sungurtekin H, Gurses E, et al. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care, 2003, 7(1):85-90.
  • 7Lorrot M, Moulin F, Coste J, et al. Procalcitonin in pediatric emergencies : comparison with C- reactive protein interleukin-6 and interferon alpha in the differentiation between bacterial and viral infections. Press Med, 2000, 29(3):128-134.
  • 8Castelli G P, Pognami C, Cita M, et al. Procalcitonin as a prognostic and diagnostic tool for septic complications after major trauma. Crit Care Med, 2009, 37(6) :1845-1849.
  • 9Rumende C M, Mahdi D. Role of combined procalcitonin and lipopolysaccharde-binding protein as prognostic markers of mortality in patients with ventilator-associated pneumonia. Acta Med Indones, 2013, 45(2) :89-93.
  • 10Landesberg G, Gilon D, Meroz Y, et al. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J, 2012, 33 (7) :895-903.

共引文献50

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部